How to buy Edwards Lifesciences Corporation shares

Own Edwards Lifesciences Corporation shares in just a few minutes. Share price changes are updated daily.

Fact checked

Edwards Lifesciences Corporation (EW) is a leading medical devices business based in the US. Edwards Lifesciences Corporation is listed on the NYSE and employs 13,900 staff. All prices are listed in US Dollars.

How to buy shares in Edwards Lifesciences Corporation

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: EW in this case.
  5. Research Edwards Lifesciences Corporation shares. The platform should provide the latest information available.
  6. Buy your Edwards Lifesciences Corporation shares. It's that simple.
The whole process can take as little as 15 minutes.

Edwards Lifesciences Corporation share price

Use our graph to track the performance of EW stocks over time.

Edwards Lifesciences Corporation shares at a glance

Information last updated 2021-01-23.
52-week range$51.5067 - $92.08
50-day moving average $87.5027
200-day moving average $81.5104
Wall St. target price$94.35
PE ratio 67.6047
Dividend yield N/A (0%)
Earnings per share (TTM) $1.265
Promoted
eToro Free Stocks

Invest in Edwards Lifesciences Corporation shares with 0% commission

Other fees may apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • If your trades get copied you can earn extra money
  • Create an account today in a few minutes

Share dealing platform comparison

Table: sorted by promoted deals first
Data indicated here is updated regularly
Name Product Price per trade Frequent trader rate Platform fees Brand description
Fineco
£2.95
£2.95
Zero platform fee
Your first 100 trades are free with Fineco, T&Cs apply.
Fineco Bank is good for share traders and investors looking for a complete platform and wide offer. Capital at risk.
eToro Free Stocks
0% commission, no markup, no ticket fee, no management fee
N/A
Withdrawal fee & GDP to USD deposit conversion
Capital at risk. 0% commission but other fees may apply.
Stake
£0
£0
Zero platform fee
Join and receive a free share worth up to £100
Access unlimited commission-free trading on 3,800+ US stocks and ETFs with Stake. Capital at risk.
IG
0% commission on US shares, and £3 on UK shares
From £5
£0 - £24 per quarter
IG is good for experienced traders, and offers learning resources for beginners, all with wide access to shares, ETFs and funds. Capital at risk.
Degiro Share Dealing
£1.75 + 0.022% (max £5.00)
£1.75 + 0.022% (max £5.00)
Portfolio transfer fees (in & out)
Degiro is widely seen as one of the best low-cost share brokers, for people who are looking to trade regularly. Capital at risk.
Hargreaves Lansdown Fund and Share Account
£11.95
£5.95
No fees
Hargreaves Lansdown is the UK's number one platform for private investors, with the depth of features you'd expect from an established platform. Capital at risk.
Interactive Investor
From £7.99 on the Investor Service Plan
From £7.99 on the Investor Service Plan
No transfer fees or exit fees. £9.99 a month on the Investor Service Plan
Open an ISA, Trading Account or SIPP you will get £100 of free trades to buy or sell any investment (new customers only).
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum deposit Maximum annual fee Price per trade Brand description
Interactive Investor stocks and shares ISA
Any lump sum or £25 a month
£119.88
£7.99
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
Moneyfarm stocks and shares ISA
£1500
0.75%
£0
Moneyfarm helps you meet your investment goals with fully-managed portfolios designed around you. Capital at risk.
Hargreaves Lansdown stocks and shares ISA
£100
0.45%
£11.95
Hargreaves Lansdown is the UK's biggest wealth manager. It's got everything you'll need, from beginners to experienced investors. Capital at risk.
Nutmeg stocks and shares ISA
£100
0.75%
£0
Nutmeg offers three types of portfolios. Choose the one that goes with your investment style. Capital at risk.
Saxo Markets stocks and shares ISA
No minimum deposit requirement
0.12%
£8.00
Saxo Markets offers a wide access to a range of stocks, ETFs and funds. Capital at risk.
AJ Bell stocks and shares ISA
£500
0.25%
£9.95
AJ Bell is a good all-rounder for people who to choose between shares, funds, ISAs and pensions. Capital at risk.
Fidelity stocks and shares ISA
£1000 or a regular savings plan from £50
0.35%
£10.00
Fidelity is another good all-rounder, offering a good package at a decent price. Not suited for trading shares. Capital at risk.
Legal & General stocks and shares ISA
Legal & General stocks and shares ISA
£100 or £20 a month
0.61%
N/A
Legal & General is a big financial services company which offers insurance, lifetime mortgage, pensions and stocks and shares ISAs. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum investment Choose from Annual fee Brand description
Interactive Investor Pension
Any lump sum or £25 a month
Over 3,000 funds
£10/month
interactive investor is a flat-fee platform, which makes it cost effective for larger portfolios. Capital at risk.
Moneyfarm Pension
£1,500 (initial investment)
7 funds
0.35%-0.75%
Moneyfarm has pensions that are matched against your risk appetite, goals and planned retirement date. Capital at risk.
AJ Bell Pension
£1,000
Over 2,000 funds
0.05-0.25%
AJ Bell has two different pension options, a self managed pension and one that is managed for you. Capital at risk.
PensionBee Pension
No minimum
7 funds
0.5% - 0.95%
Pension Bee is a newbie in the pension market. It helps consolidate your pension plans into one place. Capital at risk.
Hargreaves Lansdown Pension
£100 or £25 a month
2,500 funds
0-0.45%
Hargreaves Lansdown is the UK's biggest wealth manager. It's got three different retirement options. Capital at risk.
Saxo Markets Pension
Saxo Markets Pension
£10
Over 11,000 funds
No annual fee
Saxo Markets gives flexibility and control over your investment strategy. Capital at risk.
Penfold
Penfold
No minimum
4 portfolios
0.75-0.88%
Moneybox Pension
£1
3 funds
0.15% - 0.45% charged monthly
Manage your money with an easy-to-use Moneybox app. Capital at risk.
loading

Compare up to 4 providers

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is it a good time to buy Edwards Lifesciences Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is Edwards Lifesciences Corporation under- or over-valued?

Valuing Edwards Lifesciences Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Edwards Lifesciences Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Edwards Lifesciences Corporation's P/E ratio

Edwards Lifesciences Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 68x. In other words, Edwards Lifesciences Corporation shares trade at around 68x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Edwards Lifesciences Corporation's PEG ratio

Edwards Lifesciences Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.2397. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Edwards Lifesciences Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Edwards Lifesciences Corporation's EBITDA

Edwards Lifesciences Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $1.4 billion.

The EBITDA is a measure of a Edwards Lifesciences Corporation's overall financial performance and is widely used to measure a its profitability.

Edwards Lifesciences Corporation financials

Revenue TTM $4.4 billion
Operating margin TTM 29.85%
Gross profit TTM $3.2 billion
Return on assets TTM 12.77%
Return on equity TTM 19.79%
Profit margin 18.18%
Book value $6.759
Market capitalisation $53.3 billion

TTM: trailing 12 months

How to short and sell Edwards Lifesciences Corporation shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "EW.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 4.6 million Edwards Lifesciences Corporation shares held short by investors – that's known as Edwards Lifesciences Corporation's "short interest". This figure is 12.9% down from 5.3 million last month.

There are a few different ways that this level of interest in shorting Edwards Lifesciences Corporation shares can be evaluated.

Edwards Lifesciences Corporation's "short interest ratio" (SIR)

Edwards Lifesciences Corporation's "short interest ratio" (SIR) is the quantity of Edwards Lifesciences Corporation shares currently shorted divided by the average quantity of Edwards Lifesciences Corporation shares traded daily (recently around 2.2 million). Edwards Lifesciences Corporation's SIR currently stands at 2.09. In other words for every 100,000 Edwards Lifesciences Corporation shares traded daily on the market, roughly 2090 shares are currently held short.

However Edwards Lifesciences Corporation's short interest can also be evaluated against the total number of Edwards Lifesciences Corporation shares, or, against the total number of tradable Edwards Lifesciences Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Edwards Lifesciences Corporation's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Edwards Lifesciences Corporation shares in existence, roughly 10 shares are currently held short) or 0.0076% of the tradable shares (for every 100,000 tradable Edwards Lifesciences Corporation shares, roughly 8 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Edwards Lifesciences Corporation.

Find out more about how you can short Edwards Lifesciences Corporation stock.

Edwards Lifesciences Corporation's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Edwards Lifesciences Corporation.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Edwards Lifesciences Corporation's total ESG risk score

Total ESG risk: 21.68

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Edwards Lifesciences Corporation's overall score of 21.68 (as at 01/01/2019) is pretty good – landing it in it in the 24th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Edwards Lifesciences Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Edwards Lifesciences Corporation's environmental score

Environmental score: 4.78/100

Edwards Lifesciences Corporation's environmental score of 4.78 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Edwards Lifesciences Corporation is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Edwards Lifesciences Corporation's social score

Social score: 13.43/100

Edwards Lifesciences Corporation's social score of 13.43 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Edwards Lifesciences Corporation is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Edwards Lifesciences Corporation's governance score

Governance score: 10.96/100

Edwards Lifesciences Corporation's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Edwards Lifesciences Corporation is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Edwards Lifesciences Corporation's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Edwards Lifesciences Corporation scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Edwards Lifesciences Corporation has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Edwards Lifesciences Corporation was last rated for ESG on: 2019-01-01.

Total ESG score 21.68
Total ESG percentile 24.1
Environmental score 4.78
Environmental score percentile 6
Social score 13.43
Social score percentile 6
Governance score 10.96
Governance score percentile 6
Level of controversy 2

Edwards Lifesciences Corporation share dividends

We're not expecting Edwards Lifesciences Corporation to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

Have Edwards Lifesciences Corporation's shares ever split?

Edwards Lifesciences Corporation's shares were split on a 3:1 basis on 1 June 2020. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Edwards Lifesciences Corporation shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Edwards Lifesciences Corporation shares which in turn could have impacted Edwards Lifesciences Corporation's share price.

Edwards Lifesciences Corporation share price volatility

Over the last 12 months, Edwards Lifesciences Corporation's shares have ranged in value from as little as $51.5067 up to $92.08. A popular way to gauge a stock's volatility is its "beta".

EW.US volatility(beta: 0.97)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Edwards Lifesciences Corporation's is 0.9732. This would suggest that Edwards Lifesciences Corporation's shares are less volatile than average (for this exchange).

Win £500 to get your trading started

Subscribe to trending stock alerts for a chance to win

By submitting, you agree to the Finder Privacy and Cookies Policy and Terms of Use

Edwards Lifesciences Corporation overview

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral valve diseases, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Frequently asked questions

More guides on Finder

  • How to buy Transportation and Logistics Systems shares

    Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.

  • How to buy Charlie’s Holdings shares

    Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.

  • How to buy Lemonade shares

    Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.

  • How to buy Unity Software shares

    Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor

  • How to buy FuelCell Energy shares

    Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.

  • How to buy CloudCommerce shares

    Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor

  • How to buy Zomedica Pharmaceuticals shares

    Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.

  • How to buy YRC Worldwide shares

    Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.

  • How to buy Xeros Technology Group shares

    Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.

  • How to buy Xpediator shares

    Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site